摘要
目的探讨培美曲塞联合铂类治疗晚期复发性非小细胞肺癌(NSCLC)的疗效以及不良反应。方法经病理学或细胞学确诊的复发性晚期NSCLC患者12例,培美曲塞500 mg/m2第1天静脉滴注,卡铂(AUC=5)第1天静脉滴注或顺铂75 mg/m2每4周重复,至少应用2个周期以上评价疗效及不良反应。结果 12例患者,完全缓解1例,部分缓解2例,稳定5例,进展4例。缓解率25%,疾病控制率66.7%。不良反应主要为轻中度的胃肠道反应和骨髓抑制。结论培美曲塞联合铂类治疗晚期复发性非小细胞肺癌疗效确切,不良反应可耐受。
Objective To observe the efficacy of pemetrexed combined with cisplatin/carboplatin chemotherapy in patients with advanced recurrent non-small cell lung cancer（NSCLC）.Methods Twelve patients with advanced recurrent NSCLC were given chemotherapy with pemetrexed 500 mg/m 2,d1,carboplatin（AUC=5）,d1 or cisplatin 75 mg/m 2,d1,four weeks for a cycle.Results Twelve patients were evaluated with 25% response rate（CR 1/12;PR 2/12）.The stable disease rate was 66.7%.The common adverse effects were leucopenia and gastrointestinal response.Conclusion Chemotherapy with pemetrexed combined with cisplatin/carboplatin is effective and feasible for advanced recurrent NSCLC.So pemetxed is one of the choices for NSCLC patients who need two or more line therapy.
出处
《临床医学》
CAS
2010年第12期32-34,共3页
Clinical Medicine
关键词
培美曲塞
复发
晚期非小细胞肺癌
卡铂/顺铂
Pemetrexed
Recurrence
Advanced non-small cell lung cancer
Carboplatin/cisplatin
